Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2209)	5/27/1999 9:35:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 2742

That's silly. CIST no longer has a reagents business. There is no synergy. It was proposed, ages ago, that Endogen would have been a good merger candidate with CIST. That was before Galton, in all his wisdom, licensed IL-1beta to Peprotech. I don't hold any shares of CIST, and I haven't for a long, long time....... not since it became obvious that Galton couldn't or wouldn't drive a business plan forward. You simply need to go to Mr. Rothschild and ask if Naismith gave away the entirety of adjuvancy for that pittance. If not, then there's something in addition to the cash to work with. I proposed a company that was perfect for a reverse merger over a year ago. I posted the name of the company here and gave it to Hal Smith. There are other companies out there that "have antigens, will travel". If he did give away all of adjuvancy, then all you can do is sell the cash. It is simply amazing how arrogant men can destroy a company and yet walk with a large fraction of the remains.